profit from every $100 of sales.
$0$100
Sotera Health
$16.61+1.90% today
+3.7% in 1 year
1-year low $13.131-year high $19.57
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $60.86 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sotera Health sold, what it kept, and what it did with the cash.
Sales went from $1.00 billion in 2022 to $1.16 billion in 2025, with $77.9 million of profit last year.
SalesProfit
Sotera Health vs. similar companies
Sotera Health grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sotera Health | 60.9× · Very expensive | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Sotera Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 818 | 931 | 1,004 | 1,049 | 1,100 | 1,164 | |
| 444 | 519 | 557 | 577 | 602 | 646 | |
| 206 | 257 | 248 | 277 | 298 | 362 | |
| – | – | -17 | 407 | 442 | 440 | |
| -39 | 117 | -234 | 51 | 44 | 78 | |
| -0.16 | 0.41 | -0.83 | 0.18 | 0.16 | 0.27 | |
| 54.2% | 55.7% | 55.5% | 55.0% | 54.7% | 55.5% | |
| 25.2% | 27.6% | 24.7% | 26.4% | 27.0% | 31.1% | |
| -4.7% | 12.5% | -23.3% | 4.9% | 4.0% | 6.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,761 | 2,790 | 3,118 | 3,130 | 3,072 | 3,263 |
| Cash | 102 | 107 | 395 | 296 | 277 | 345 |
| Total debt | 1,825 | 1,786 | 2,032 | 2,327 | 2,351 | 2,274 |
| Total liabilities | 2,307 | 2,203 | 2,767 | 2,687 | 2,667 | 2,657 |
| 452 | 586 | 350 | 444 | 405 | 606 | |
| 238 | 279 | 280 | 283 | 285 | 286 | |
| – | – | -5.4% | 7.1% | 8.0% | 8.3% | |
| -8.5% | 19.9% | -66.7% | 11.6% | 11.0% | 12.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 121 | 282 | 278 | -148 | 224 | 287 | |
| 54 | 102 | 182 | 215 | 179 | 138 | |
| 67 | 179 | 96 | -363 | 45 | 149 | |
| Dividends paid | 0 | 0 | – | – | – | – |
| 34 | 0 | 0 | 4 | 4 | – | |
| 11 | 14 | 21 | 32 | 37 | 31 |
Valuation
- 60.9×
- 17.2×
- –
- 7.0×
- 4.1×
- 31.8×
- 15.2×
- 3.1%
- 1.6%
- 0.0%
Profitability
- 55.5%
- 31.1%
- 6.7%
- 41.9%
- 8.0%
- 0.2%
- 20.6%
- 3.6%
- 13.9%
- –
Growth
- +7.3%
- –
- +230.8%
- –
- +0.4%
Financial health
- 3.9×
- 3.65
- 70.2%
- 2.8×
- 2.82
- 2.52
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 40%of 963
Top 9%of 894
Bottom 18%of 632
Bottom 38%of 908
Top 36%of 991
What analysts expect
- Average price target
- $22.00
- Range
- $18.00 – $24.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.18 | 0.17 | +5.9% |
| Feb 24, 2026 | 0.26 | 0.24 | +8.3% |
| Nov 4, 2025 | 0.26 | 0.22 | +18.2% |
| Aug 8, 2025 | 0.20 | 0.17 | +17.6% |
| May 1, 2025 | 0.14 | 0.12 | +16.7% |
| Feb 27, 2025 | 0.21 | 0.21 | +0.0% |
| Nov 5, 2024 | 0.17 | 0.19 | −10.5% |
| Aug 5, 2024 | 0.19 | 0.17 | +11.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
17No pass
Philip Fisher
41No pass
Peter Lynch
28No pass
Joel Greenblatt
20No pass
Charlie Munger
37No pass
Terry Smith
43No pass
Questions about Sotera Health
Is Sotera Health a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sotera Health AI analysis
What does Sotera Health do?
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. It is in Medical - Diagnostics & Research, based in Broadview Heights, OH, United States, with 3,000 employees.
Does Sotera Health pay a dividend?
No. Sotera Health does not pay a dividend at the moment.
Is Sotera Health stock halal?
No. Sotera Health does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has Sotera Health stock done over the past year?
Up 3.7% over the past twelve months, to $16.61. It traded between $13.13 and $19.57 and is 15.1% below its high.
Who are Sotera Health's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Sotera Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.